Gefticip (Gefitinib 250mg Tablets)

Gefticip (Gefitinib 250mg Tablets)

Gefticip (Gefitinib 250mg Tablets) is used in the treatment of lung cancer. It helps to treat non-small-cell lung cancer by blocking the action of an enzyme known as tyrosine kinase. This enzyme is believed to be needed by the cancer cells to multiply, so by interfering with its function the medication helps to prevent the growth of cancer cells and slow down their ability to spread throughout the lungs and beyond.

Uses Gefticip (Gefitinib 250mg Tablets)?

Gefticip (Gefitinib 250mg Tablets) is taken orally, and washed down with a full glass of water. It may be taken either on an empty stomach or alongside a meal or snack. Patients taking this medication normally require frequent blood tests during the course of their treatment, and you should always attend all appointments for tests and checkups. This medication should only be taken as directed by your physician. Patients should always take the exact dose prescribed to them, and ensure that they do not miss any doses.

Gefticip (Gefitinib 250mg Tablets) works

Gefticip (Gefitinib 250mg Tablets) blocks a protein called ‘epidermal growth factor receptor’ (EGFR) which is involved in the growth and spread of cancer cells.

Side Effects of Gefticip (Gefitinib 250mg Tablets)?

Some side effects have been reported by patients taking Gefticip (Gefitinib 250mg Tablets) and these include mild nausea, fatigue, acne, and hair loss. Consult your physician immediately if you notice any of the following rare but serious side effects:

• Coughing up blood or blood visible in urine
• Bloody or black stools
• Eye pain
• Fever
• Difficulty breathing

Gefticip (Gefitinib 250mg Tablets) Dosage and Administration

The recommended daily dose of Gefticip (Gefitinib 250mg Tablets) is one 250 mg tablet with or without food. Higher doses do not give a better response and cause increased toxicity. If a dose of Gefticip (Gefitinib 250mg Tablets) is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.

Gefticip (Gefitinib 250mg Tablets) Dosage Adjustment

1. Patients with poorly tolerated diarrhoea (sometimes associated with dehydration) or skin adverse drug reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg daily dose.
2. In the event of acute onset or worsening of pulmonary symptoms (dyspnoea, cough, fever), Gefticip (Gefitinib 250mg Tablets) therapy should be interrupted and a prompt investigation of these symptoms should occur and appropriate treatment initiated. If interstitial lung disease (ILD) is confirmed, Gefticip (Gefitinib 250mg Tablets) should be discontinued and the patient treated appropriately.
3. Patients who develop an onset of eye symptoms such as pain should be medically evaluated and managed appropriately, including interruption of Gefticip (Gefitinib 250mg Tablets) therapy and removal of an aberrant eyelash, if present. After the symptoms and eye changes have resolved, the decision should be made concerning reinstatement of the 250 mg daily dose.
4. In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reactions, and clinical response and adverse events should be carefully monitored.
5. No dosage adjustment is required on the basis of patient age, body weight, gender, ethnicity or renal function, or in patients with moderate-to-severe hepatic impairment due to liver metastases.

Paediatric Population

The safety and efficacy of Gefticip (Gefitinib 250mg Tablets) in children and adolescents aged less than 18 years has not been established. There is no relevant use of Gefticip (Gefitinib 250mg Tablets) in the paediatric population in the indication of nsclc.

Hepatic Impairment

Patients with moderate-to-severe hepatic impairment (Child-Pugh B or C) due to cirrhosis have increased plasma concentrations of gefitinib. These patients should be closely monitored for adverse events. Plasma concentrations were not increased in patients with elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to liver metastases.

Renal Impairment

No dose adjustment is required in patients with impaired renal function at creatinine clearance >20 ml/min. Only limited data are available in patients with creatinine clearance ≤20 ml/min and caution is advised in these.

Elderly

No dose adjustment is required on the basis of the patient's age.

Dose Adjustment Due to Toxicity

Patients with poorly tolerated diarrhoea or skin adverse reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg dose. For patients unable to tolerate treatment after a therapy interruption, Gefticip (Gefitinib 250mg Tablets) should be discontinued and an alternative treatment should be considered.

Warning & Precautions :

• Before starting Gefticip (Gefitinib 250mg Tablets) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.)
• Tell your doctor if you have or have ever had pulmonary fibrosis (scarring of the lungs) or other lung or breathing problems, eye or vision problems, or liver disease.
• Do not breast feed while taking this medication.
• You must try to keep your regular appointments with your doctor or hospital. This is so your doctor can check on your progress.

If you are having an operation or dental treatment, always tell the person carrying out the treatment which medicines you are taking.

• Availability: In Stock
• Model: Gefticip
• Brand: Cipla